BioNet-Asia Co., Ltd
BioNet is a Franco‑Thai biotechnology group focused on development, GMP manufacturing and international supply of genetically designed vaccines. The organization advances recombinant and mRNA vaccine platforms from antigen design through clinical development and large‑scale production, and operates manufacturing sites and quality systems certified to international GMP standards.
Industries
N/A
Nr. of Employees
small (1-50)
BioNet-Asia Co., Ltd
41 Cours de la Liberté 69003 Lyon Cedex 03, France
Products
Pertagen
Licensed recombinant monovalent acellular pertussis vaccine containing genetically inactivated pertussis toxin; included in maternal immunization programs in Thailand and licensed in parts of Asia.
Boostagen
Tetanus toxoid, reduced diphtheria toxoid, recombinant pertussis combination vaccine (Tdap) developed and manufactured as part of the recombinant pertussis portfolio.
Recombinant pertussis vaccine candidate under EMA review
Monovalent recombinant pertussis vaccine submitted for centralized marketing authorization review by EMA (candidate name referenced in press materials).
Pertagen
Licensed recombinant monovalent acellular pertussis vaccine containing genetically inactivated pertussis toxin; included in maternal immunization programs in Thailand and licensed in parts of Asia.
Boostagen
Tetanus toxoid, reduced diphtheria toxoid, recombinant pertussis combination vaccine (Tdap) developed and manufactured as part of the recombinant pertussis portfolio.
Recombinant pertussis vaccine candidate under EMA review
Monovalent recombinant pertussis vaccine submitted for centralized marketing authorization review by EMA (candidate name referenced in press materials).
Services
On-site GMP production of recombinant and mRNA vaccine material and clinical/GMP lot manufacturing with in-house quality control.
Co-development agreements, manufacturing partnerships and supply arrangements to expand regional vaccine access.
On-site GMP production of recombinant and mRNA vaccine material and clinical/GMP lot manufacturing with in-house quality control.
Co-development agreements, manufacturing partnerships and supply arrangements to expand regional vaccine access.
Expertise Areas
- Recombinant vaccine development
- mRNA vaccine platform development
- GMP biomanufacturing and quality systems
- Clinical trial management and maternal immunization studies
Key Technologies
- Recombinant vaccine technology
- mRNA vaccine platform (plug-and-play)
- DNA vaccine platforms
- Microneedle patch delivery (dissolvable)
News & Updates
Memorandum of Understanding signed to co-develop and distribute Tdap vaccines in Southeast Asia, combining recombinant vaccine expertise with large-scale manufacturing.
Announcement of receipt of European Union Good Manufacturing Practice certification for production of acellular recombinant pertussis vaccine following HPRA inspection.
Recognition and funding award for a collaboration to integrate mRNA vaccine technology with dissolvable microneedle patch delivery for influenza and pandemic preparedness.
Received EU‑GMP certification confirming facilities and quality systems meet international GMP criteria.
Concept-stage winner status and funding award for microneedle mRNA vaccine platform collaboration.
Memorandum of Understanding signed to co-develop and distribute Tdap vaccines in Southeast Asia, combining recombinant vaccine expertise with large-scale manufacturing.
Announcement of receipt of European Union Good Manufacturing Practice certification for production of acellular recombinant pertussis vaccine following HPRA inspection.
Recognition and funding award for a collaboration to integrate mRNA vaccine technology with dissolvable microneedle patch delivery for influenza and pandemic preparedness.
Received EU‑GMP certification confirming facilities and quality systems meet international GMP criteria.
Concept-stage winner status and funding award for microneedle mRNA vaccine platform collaboration.